India, May 30 -- As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. From January through May 2025, the U.S. regulatory agency has approved 13 novel drugs, a modest decline from the 16 approvals recorded during the same period in 2024.
The following biotech companies are awaiting potential FDA approvals in June 2025.
Merck & Co. Inc. (MRK)
The FDA is set to decide by June 10, 2025, on Merck's Clesrovimab, a long-acting monoclonal antibody developed to protect infants from respiratory syncytial virus (RSV) during their first RSV season.
Respiratory syncytial virus is a contagious virus that causes widespread seasonal infections like the flu in infants and older adults. There is a high unmet ...